NEWS

Mankind Pharma Limited IPO : Highlights

Mankind Pharma Limited IPO is set to launch on 25 April, 2023. The company initiated its business operations in the year 1991. It has been in the business of manufacturing, developing and marketing pharmaceutical formulations across various chronic and acute therapeutic areas and other consumer healthcare products.

The company has more than 36 brands under its name. This includes Moxikind CV, Manforce, Unwanted Kit, Amlokind AT, Gudcef, Candiforce, Prega news, Glimestar M, Codistar, Dydroboon, Nurokind, Gefakind, Asthakind, Telmikind, Monticope, Unwanted 72 etc.

It ranks 4th for the domestic sales and it also has a large network of medical representatives pan India.

Mankind Pharma Limited IPO DETAILS

Mankind Pharma Limited IPO is set to launch on 25 April, 2023. The subscription timeline extends till 27 April, 2023. The size for the IPO is 4326.36 Crore Rs. No Shares are issued through fresh issue mode. Shares issued through offer for sale mode are worth Rs 4326.36 Crore. The lot size is 13 shares and the price is 1026 to 1080 Rs per share. The company is going to get listed at both NSE and BSE. The face value per share is Re. 1 and this is a Book Built issue. The registrar for the company is KFin Technologies India Limited.

Tabular Description of Mankind Pharma Limited IPO

IPO OPENING DATE	25 April, 2023
CLOSING DATE FOR IPO	27 April, 2023
ISSUE TYPE	Book Built Issue
Face Value per share	1 Re. per share
IPO price band	1026 to 1080 Rs per share
LOT SIZE	13 shares
MINIMUM ORDER QUANTITY	13 shares
ISSUE SIZE	4326.36 Crore Rs.
OFFER FOR SALE	4326.36 Crore Rs
FRESH ISSUE	No shares issued through Fresh Issue Mode
LISTING AT	NSE, BSE
LISTING DATE	8 May, 2023

Mankind Pharma Limited IPO : IMPORTANT DATES

IPO OPENING DATE	25 April, 2023
CLOSING DATE FOR IPO	27 April, 2023
IPO ALLOTMENT DATE	3 May, 2023
REFUNDS	4 May, 2023
DEMAT A/C CREDITED ON	5 May, 2023
IPO LISTING DATE	8 May, 2023

Mankind Pharma Limited IPO begins for subscription from 25 April, 2023. The IPO subscription would continue till 27 April, 2023. The allotment status for the shareholders who applied would come on 3 May, 2023. The refunds for the ones who did not get allotment would be initiated on 4 May, 2023. The DEMAT accounts of shareholders would be credited on 5 May, 2023. The listing of the company would be accompanied on 8 May, 2023.

Mankind Pharma Limited IPO : Lead Managers

The lead managers are :

Kotak Mahindra Capital Company Limited
J.P. Morgan India Private Limited
Axis Capital Limited
Jefferies India Private Limited
IIFL Securities Limited

The minimum lot size for the company is decided at 13 shares. This holding accounts to 14040 Rs.. The maximum lot size is decided at 182 shares. This amounts to 196560 Rs.. Hence the company’s final holdings would be set as :

	Shares	Amount
Minimum	13 shares	14040 Rs.
Maximum	182 shares	196560 Rs.

OBJECTIVES FOR THE IPO

No money will be going to the company rather it will all be going to the Selling Shareholders.

COMPANY FINANCIALS

Particularly (in Crore Rs.)	2019-20	2020-21	2021-22
ASSETS	5073	6372	9148
Revenue	5975	6385	7978
PAT	1056	1293	1452

Mankind Pharma Limited had an asset base of 5073 Crore Rs in 2020. The company’s assets increased to 6372 Crore Rs in 2021 and 9148 Crore Rs in 2022. Apart from this the revenue of the firm was 5975 Crore Rs in 2020 which increased to 6385 Crore Rs in 2021 and 7978 Crore Rs in 2022. The profits of the firm were 1056 Crore Rs in 2020, 1293 Crore Rs in 2021 and 1452 Crore Rs in 2022.

PROS

The company has more than 36 brands under its name. This includes Moxikind CV, Manforce, Unwanted Kit, Amlokind AT, Gudcef, Candiforce, Prega news, Glimestar M, Codistar, Dydroboon, Nurokind, Gefakind, Asthakind, Telmikind, Monticope, Unwanted 72 etc.
Mankind pharma ranks 4th for the domestic sales and it also has a large network of medical representatives pan India.
The company has been awarded with multiple awards since its incorporation like The best of Bharat Award 2022 and more.